Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by G1945Von Jan 05, 2025 7:43am
76 Views
Post# 36388209

RE:RE:RE:RE:ARIA-E

RE:RE:RE:RE:ARIA-E
Hafness wrote:

aria-e would be a side effect in healthy subjects as well I would think. I pretty sure this would show up in 1-a. Aria is the number one issue with these drugs. They surely were looking for it. What am I missing. 
 

here is a good article talking about aria


https://pmc.ncbi.nlm.nih.gov/articles/PMC3693547/



"aria-e would be a side effect in healthy subjects as well I would think."

I don't see why not!

I know from publications that before the trial begins, a baseline MRI scan is performed to establish a reference point for each healthy participant. During the trial, participants undergo MRI scans to monitor for any changes in the brain. This will detect any abnormalities, by observing ARIA at different doses.

G1945V
<< Previous
Bullboard Posts
Next >>